Guggenheim raised the firm’s price target on Cogent Biosciences (COGT) to $20 from $17 and keeps a Buy rating on the shares, citing increased conviction in the gastrointestinal stromal tumor opportunity following the recent announcement of positive topline data from the Phase 3 SUMMIT study of bezuclastinib. The firm, which thinks bezuclastinib in combination with sunitinib appears well-positioned for success in the PEAK study, believes “some modest value for GIST” is reflected in the current valuation, but sees an “asymmetric risk/reward” heading into the PEAK data readout.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright
- Cogent Biosciences Reports Increased Losses Amidst Ongoing Development
- Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences
- Cogent Biosciences reports Q2 net loss $73.529M vs $58.95M last year
- Promising Developments and Undervaluation Drive Buy Rating for Cogent Biosciences